18 published articles
The 2026 bibliometric and evidence-based review (PMC13068985) confirms that tirzepatide — a dual GIP/GLP-1 receptor agonist — produces MASH resolution in 44–62% of participants across dose arms versus 10% placebo, with fibrosis-stage improvement in 55–62% versus 30% placebo. Its dual incretin mechanism distinguishes it from single-agonist comparators in protocol design.
The FDA's Pharmacy Compounding Advisory Committee (PCAC) convened July 23–24, 2026 to evaluate BPC-157 and TB-500 for the 503A Bulk Drug Substances List — a regulatory gate, not an approval. Inclusion would permit licensed compounding pharmacies to prepare these peptides under individual prescriptions, but it does not alter WADA's prohibition, eliminate immunogenicity concerns, or validate any specific athlete recovery protocol.
A 2026 critical analysis published in Pharmaceuticals (MDPI) maps two competing off-target profiles for semaglutide: a context-dependent oncogenic signal concentrated in thyroid C-cells and pancreatic tissue, and a robust cardioprotective mechanism that attenuates chemotherapy-induced and ischemia-driven cardiac injury via GLP-1 receptor–mediated PI3K/AKT and NF-κB suppression. Protocol designers must account for both vectors simultaneously.
On April 22, 2026, the FDA removed BPC-157 from Category 2 of the 503A bulk drug substances list, ending its interim compounding authorization. For protocol designers targeting ulcerative colitis or chronic pain, licensed compounding is no longer legally straightforward. Rebuilding requires mapping mechanistic substitutes — primarily KPV, TB-500, and GHK-Cu — against the pathways BPC-157 previously covered.
Based on preclinical data available through 2026, BPC-157 and TB-500 drive tendon and ligament repair through mechanistically distinct angiogenic pathways — neither compound has been validated in a controlled human trial. BPC-157 operates via FAK-paxillin and VEGFR2 signalling at the injury site; TB-500 acts systemically through G-actin sequestration and endothelial progenitor cell recruitment. No head-to-head RCT exists.
No direct co-administration trial for semaglutide and thymosin alpha-1 (Tα1) exists as of 2026. The interaction map is built from each compound's independent pharmacology: semaglutide's GLP-1R–mediated anti-inflammatory signaling and Tα1's TLR-dependent immune priming operate through non-overlapping receptor systems, making a direct pharmacodynamic collision unlikely but formally uncharacterised.